{"product_id":"current-and-future-issues-in-hemophilia-care-9780470670576","title":"Current and Future Issues in Hemophilia Care","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eAs haemophilia is a life-long condition, continuing supervision by a group of medical personnel is required. In many countries this is provided by comprehensive care haemophilia centres where staff of all specialities concerned with treatment- haematologists, paediatricians, nurses, physiotherapists, orthopaedic surgeons - have specialized knowledge.    This new book is a definitive resource on the current aspects and issues around haemophilia. Complications of haemophilia care are well covered in chapters on inhibitors, and musculoskeletal problems, as are all the latest developments in the field of haemophilia.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eList of Contributors.  \u003cp\u003ePreface.\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1: INTRODUCTION.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 History of Hemophilia (\u003ci\u003eCaroline Cromwell and Louis Aledort\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e2 Hemophilia Care in the Modern World (\u003ci\u003eChristine A. Lee\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e3 Comprehensive Care Model in Hemophilia (\u003ci\u003ePrasad Mathew\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2: GENERAL TOPICS.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e4 When Should We Switch From On-Demand to Prophylaxis Regimen? (\u003ci\u003eJosé A. Aznar, Andres Moret, Lydia Abad-Franch, Ana Rosa Cid, Saturnino Haya and Felipe Querol\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e5 Prophylaxis in Children (\u003ci\u003eM. Manco-Johnson\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e6 Prophylaxis in Adults with Hemophilia (\u003ci\u003eVictor Jiménez -Yuste, Emérito-Carlos Rodríguez-Merchán, Maria-Teresa Alvarez-Román, Monica Martín –Salces\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e7 The Economics of Prophylaxis: Does Prophylaxis with Clotting Factor Represent Value for Money? (\u003ci\u003eAlec Miners\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e8 The Transition of Care for the Young Adult Hemophilia Patient (\u003ci\u003ePia Petrini\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e9 Perinatal Clinical Care and Molecular Diagnosis in Hemophilia (\u003ci\u003eCarmen Altisent and Francisco Vidal\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e10 Managing the Mature Person with Hemophilia (\u003ci\u003eSavita Rangarajan and Thynn Thynn Yee\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e11 Quality of Life in Hemophilia (\u003ci\u003eEduardo Remor\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3: INHIBITORS.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e12 Immunology of Inhibitor Development (\u003ci\u003eBirgit M Reipert, Christoph J Hofbauer, Katharina N Steinitz, Hans-Peter Schwarz, FM Horling\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e13 Epidemiology of Inhibitors (\u003ci\u003eJohanna G. Van der Bom\u003c\/i\u003e)\u003c\/p\u003e \u003cp\u003e14 Early Tolerisation to Minimise Inhibitors in PUPS with Hemophilia A (\u003ci\u003eGünter Auerswald and Karin Kurnik\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e15 Prediction of Inhibitors in Severe Hemophilia (\u003ci\u003eH. Marijke van den Berg and Kathelijn Fischer\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e16 Genetic basis for Inhibitor Development (\u003ci\u003eJohannes Oldenburg and Anna Pavlova\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e17 Non-Genetic Risk Factors for Inhibitor Development (\u003ci\u003eLisa N. Boggio and Mindy L. Simpson\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 4: INHIBITOR TREATMENT.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e18 Immune Tolerance Induction Programmes (\u003ci\u003eJan Blatny and Prasad Mathew\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e19 Prophylaxis in Hemophilia A Patients with Inhibitors (\u003ci\u003eLeonard A. Valentino and Guy Young\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e20 Treatment of Bleeding in FVIII Inhibitor Patients (\u003ci\u003ePaul Giangrande and Jerome Teitel\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e21 Discordancy of By-Passing Therapy (\u003ci\u003eJan Astermark\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 5: JOINT HEALTH AND DISEASE.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e22 Experimental Studies on Hemarthrosis, Synovitis and Arthropathy (\u003ci\u003eLeonard A. Valentino and Narine Hakobyan\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e23 Assessment of Joint Involvement in Hemophilia (\u003ci\u003eErik Berntorp\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e24 Imaging of the Hemophilic Joint (\u003ci\u003eCarmen Martín-Hervásand Emérito-Carlos Rodríguez-Merchán\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e25 Initial and Advanced Stages of Hemophilic Arthropathy, and Other Musculo-Skeletal Problems: the Role of Orthopedic Surgery (\u003ci\u003eEmérito-Carlos Rodríguez-Merchán, VictorJiménez -Yuste and Nicholas J. Goddard\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e26 Perioperative Thromboprophylaxis for Persons with Hemophilia Undergoing Orthopaedic Surgery (\u003ci\u003eGerry Dolan, Donna M. Dimichele and Emérito-Carlos Rodríguez-Merchán\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 6: NEW DEVELOPMENTS.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e27 New Technologies for the Pharmacokinetic Improvement of Coagulation Factor Proteins (\u003ci\u003eLeonard A. Valentino\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e28 Current and Future Approaches to Gene Therapy in Patients with Hemophilia (\u003ci\u003eMaria-Teresa Alvarez- Román, Monica Martín-Salces, Victor Jiménez -Yuste and Emérito-Carlos Rodríguez-Merchán\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e29 New Developments in Hemophilic Arthropathy (\u003ci\u003eEmérito-Carlos Rodríguez-Merchán and Leonard A. Valentino\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e30 Physiotherapy Evaluation and Intervention in the Acute Hemarthrosis:  Challenging the Paradigm (\u003ci\u003eNichan Zourikian and Angela L. Forsyth\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e31 Laboratory Assays to Predict Response to Bypassing Agents (\u003ci\u003eBenny Sørensen and Claude Negrier\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e32 Combination\/Sequential Use of Bypassing Agents (\u003ci\u003eAlessandro Gringeri\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eIndex.\u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":49525386117463,"sku":"9780470670576","price":76.9,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780470670576.jpg?v=1731860317","url":"https:\/\/bookcurl.com\/products\/current-and-future-issues-in-hemophilia-care-9780470670576","provider":"Book Curl","version":"1.0","type":"link"}